Lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. As these cells grow, they form tumors. When cells from the tumor travel through the body, the cancer spreads. When cancer spreads to other parts of the body, it’s called “advanced” or cancer.
In the US, the chance that a woman will develop lung cancer at some point in her life is 1 in 17. The chance that a man will is 1 in 16. These numbers include both people who smoke and those who don't smoke. Lung cancer can happen to anyone, regardless of smoking history.
About non–small cell lung cancer
The 2 most common types of lung cancer are non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The difference between these types is how the cancer cells look under a microscope. There may be different treatments approved for use for each. NSCLC is the most common type of lung cancer. About 80% to 85% of all lung cancer cases are NSCLC.
Biomarker testing may help your doctor identify the appropriate treatment
A is any molecule that can help show when your body is working normally or abnormally. This includes in certain cells associated with advanced NSCLC.
A identifies biomarkers by testing body tissue, blood or other bodily fluids and can help your doctor determine which treatment is best for you. If your tumor tests positive for EGFR exon 19 deletions or exon 21 L858R substitution mutations (sometimes referred to as "common") or the RYBREVANT® may be right for you. Ask about biomarker testing at your next doctor’s appointment.
About EGFR mutations
A protein called an epidermal growth factor receptor (EGFR) is found on both normal cells and cancer cells. It drives cells to survive and grow. EGFR mutations may cause cancer cells to overgrow and spread to other parts of the body.
RYBREVANT® can be used alone or in combination with other medicines to treat advanced non–small cell lung cancer with certain EGFR mutations.
EGFR exon 19 deletions/exon 21 L858R mutations (common)
There are 2 EGFR mutations that represent 80% to 90% of all EGFR mutations in NSCLC, so they’re known as “common” EGFR mutations. These are called “exon 19 deletion” and “exon 21 L858R.”EGFR exon 20 insertion mutations
There are other, less common mutations. One kind of EGFR mutation is called an “exon 20 insertion” mutation. While rare, exon 20 insertion mutations are the third most frequent EGFR mutation in NSCLC.
Why RYBREVANT®
See the clinical trial results, side effects, and how treatment works.Frequently asked questions (FAQs)
Here are some questions that people often have when facing non–small cell lung cancer and considering treatment with RYBREVANT®. If you have other questions, check the full FAQs page.
The 2 most common types of lung cancer are non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The difference between these types is how the cancer cells look under a microscope and the different treatments approved for use for each. NSCLC is the most common type of lung cancer. About 80% to 85% of all lung cancer cases are NSCLC. Learn more about lung cancer here.
A protein called an epidermal growth factor receptor (EGFR) is found on both normal cells and cancer cells. It drives cells to survive and grow. EGFR mutations may cause cancer cells to lose control over their growth, allowing them to multiply and spread to other parts of the body. Learn more about EGFR mutations here.
RYBREVANT® is an antibody that targets EGFR mutations. To help determine if RYBREVANT® is right for you, your doctor may perform a biomarker test. These tests can check your tumor for different biomarkers, including EGFR, and can help guide your doctor to the appropriate treatment. Learn more about biomarkers here, and ask your doctor if an EGFR biomarker test is right for you.
Doctor Discussion Guide
Tips and example questions for having a helpful discussion with your doctor.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
